Therapeutic Considerations BPC-157 is more stable than its parent compound, and studies indicate that it does not require a carrier agent to elicit systemic effects
Do KQ, Trabesinger AH, Kirsten-Kruger M, Lauer CJ, Dydak U, Hell D, et al
Studies of Chinese Han population indicated that the T allele shown associated with schizophrenia as a risk allele 52 while a casecontrol association between the MTHFR C677T polymorphism and schizophrenia in a Japanese subjects research also demonstrated a strong linkage between the MTHFR C677T polymorphism and schizophrenia 53
Twice-weekly dosing may suit patients with rapid clearance but does not dramatically increase efficacy
Weight loss often becomes steadier once you reach higher therapeutic doses
Turnaround: Typically 510 business days for results